EGFR and ovarian carcinoma: The drug combination between RAPTA-C and the epidermal growth factor receptor (EGFR) inhibitor, erlotinib, resulted in strong synergistic inhibition of cell viability in human endothelial and human ovarian carcinoma cells [184,185].